Terms: = Lung cancer AND KMT2C, ENSG00000055609, MLL3, 58508 AND Treatment
8 results:
1. Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.
Mahdi H; Joehlin-Price A; Elishaev E; Dowlati A; Abbas A
Mol Oncol; 2021 Dec; 15(12):3545-3558. PubMed ID: 34245124
[TBL] [Abstract] [Full Text] [Related]
2. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Liu Q; Wu L; Zhang S
Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242
[TBL] [Abstract] [Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract] [Full Text] [Related]
4. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
5. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Shang Y; Li X; Liu W; Shi X; Yuan S; Huo R; Fang G; Han X; Zhang J; Wang K; Dou Z; Zhang Y; Zang A; Zhang L
Sci Rep; 2020 Nov; 10(1):20243. PubMed ID: 33219256
[TBL] [Abstract] [Full Text] [Related]
6. Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients.
Kachroo S; Shao C; Desai K; He J; Jin F; Sen S
Future Oncol; 2021 Feb; 17(4):423-433. PubMed ID: 33198513
[No Abstract] [Full Text] [Related]
7. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
[TBL] [Abstract] [Full Text] [Related]
8. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]